Acer Medical’s AI Tools Transform Eye and Bone Disease Screening Across Asia

VeriSee DR and VeriSee AMD are innovative AI-driven screening tools that are helping healthcare professionals accelerate diagnosis and improve patient care. Already deployed in over 13 countries and regions, these solutions are addressing two of the most common causes of vision loss: diabetic retinopathy and age-related macular degeneration (AMD).

These tools were developed by Dr. Yi-Ting Hsieh, a retinal specialist and consultant ophthalmologist at National Taiwan University Hospital, who brings more than two decades of experience in the field. Dr. Hsieh led the creation of VeriSee DR to enable rapid screening for diabetic retinopathy — a condition that can lead to severe vision impairment or blindness in diabetic patients.

He later introduced VeriSee AMD, which targets the early detection of AMD, a progressive condition that causes blurry vision in aging populations.

How the VeriSee Solutions Work

Using a specialized fundus camera, the system captures high-resolution retinal images without the need for pupil dilation. These images are then sent to an Acer AI-powered PC, where dedicated software analyzes them in real time. Within seconds, the AI algorithm categorizes eye conditions and ranks potential complications by severity — from moderate to severe.

VeriSee AMD currently achieves about 95% accuracy in detection. As more anonymized data from eye exams are incorporated into its AI model, its precision continues to improve.

This fast, non-invasive process eliminates the long wait times associated with traditional eye exams that require dilation and hours of observation. The portability of the system — compact enough to fit in a suitcase — and its ability to function without an internet connection make it ideal for use in remote or underserved areas, far from urban medical centers.

AI as a Complement, Not a Replacement

Dr. Hsieh stresses that AI tools are not intended to replace doctors. Instead, they serve as clinical aids that enhance diagnostic accuracy and efficiency.
"AI provides a reliable reference — a quick snapshot to assist our judgment. But it’s still up to healthcare professionals to interpret results, explain them to patients, and guide the next steps in treatment," he said.

The tools also serve as practical teaching aids for general practitioners and internal medicine doctors, especially those not specialized in ophthalmology.
"One major benefit of VeriSee DR and VeriSee AMD is their ability to visually highlight lesions, making it easier for us to educate non-specialist physicians. It saves time and enhances our ability to train new doctors on how to identify and assess eye disease," Dr. Hsieh added.

Intel-Powered Integration for Speed and Performance

The VeriSee solutions have been commercially launched by Acer Medical, a subsidiary of Acer Group in Taiwan. Acer Medical is dedicated to advancing AI-based medical imaging and bringing high-performance diagnostic tools to frontline healthcare settings, including National Taiwan University Hospital — one of Taiwan’s largest teaching hospitals with over 7,500 medical professionals.

Alongside its eye care tools, Acer Medical has introduced a third AI-powered diagnostic software: VeriOsteo OP, which detects osteoporosis through standard chest X-rays. Approved by Taiwan’s Food and Drug Administration, VeriOsteo OP uses AI to assess bone mineral density (BMD) and flag abnormalities — offering early warnings before the condition worsens.

All three solutions leverage Intel® Core™ Ultra processors and Intel’s OpenVINO™ toolkit, integrated with Acer Medical’s proprietary AI algorithms for seamless performance.

Faster Analysis with OpenVINO

Dr. Allen Lien, Chairman and CEO of Acer Medical, highlighted the performance improvements brought by Intel’s OpenVINO:
"With OpenVINO, we reduced software startup time by 70%, cut image analysis time by 90%, and lowered memory usage by 90%."

"These AI solutions allow for fast, accurate screening of eye disease and bone density issues, empowering doctors to detect abnormalities early and act quickly," he said.

Early diagnosis is especially critical for conditions like AMD, where delayed treatment can result in permanent vision loss. VeriSee DR, for example, delivers lesion detection accuracy of up to 93%, enabling timely medical intervention. Meanwhile, VeriOsteo OP helps clinicians identify bone issues using widely available chest X-rays, offering an accessible alternative to specialized bone scans.

"By applying AI algorithms to chest X-ray analysis, the system can flag areas of concern and alert physicians to the presence of osteoporosis — something that would otherwise require a dedicated scan," Dr. Lien explained.

Growing Global Reach and Clinical Adoption

Acer Medical’s AI-powered diagnostic tools are now used in more than 13 countries, including Taiwan, Thailand, Malaysia, and Indonesia, with additional regions expected to adopt the solutions following clinical validation.

National Taiwan University Hospital, located in central Taipei, plans to expand the use of these tools across more clinics and into new departments.

"Currently, we’re using these AI systems in ophthalmology, endocrinology, and family medicine. Looking ahead, we aim to apply them in geriatric care as well," said Dr. Hsieh.

As more AI healthcare solutions become globally accessible, Dr. Hsieh remains optimistic about their impact:
"It’s encouraging to see technological progress, especially in artificial intelligence. AI is not just a sophisticated gadget — it genuinely supports us in medicine and many other areas of life."

"We’ve already seen how AI can influence and transform various domains. It’s not something to fear, but rather a valuable ally that can help us improve lives and shape a better future."